More on EBS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+15,200.0% Growth)
- Ratings (6.9 Score)
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (7/30/21 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Emergent BioSolutions (NY:EBS)
Delayed: 63.51 -1.97 (3.01%)
Prev. Close $65.48  
Open$65.51 
52 Wk High$44.38 
52 Wk Low$24.47 
Day High$66.12 
Day Low$62.72 
P/E 3,175.50  
EPS$0.02 
Volume829,593 

Friends, Peers and Foes (?): JNJ, FUV, AZN, CCIV, ERI (more...)

Jun 11, 2021 04:36 PM COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Jun 11, 2021 04:35 PM COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Jun 4, 2021 04:17 PM Form S-8 Emergent BioSolutions
Jun 3, 2021 03:56 PM Entwistle & Cappucci LLP Announces It Has Filed a Securities Class Action Against Emergent BioSolutions Inc. (NYSE: EBS)
Jun 2, 2021 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact
May 27, 2021 04:40 PM Form 4 Emergent BioSolutions For: May 25 Filed by: Zoon Kathryn C
May 26, 2021 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact
May 26, 2021 06:32 AM Emergent BioSolutions (EBS) Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
May 26, 2021 06:30 AM Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
May 26, 2021 06:30 AM Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
View All Articles